

# **Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia**

Kristin Waters, PharmD, BCPS, BCPP  
University of Connecticut  
Assistant Clinical Professor

1

## **Learning Objectives**

1. Identify clinical characteristics of the behavioral symptoms of dementia (BSD) including agitation, psychosis, and sleep disturbances
2. Discuss medications currently used in the management of BSD along with emerging pharmacologic therapy options
3. Determine the most appropriate pharmacologic treatment option for a patient with behavioral symptoms of dementia based on patient-specific factors

2

## Disclosures

- Dr. Waters is a paid speaker for Johnson & Johnson. All financial interests with ineligible companies have been mitigated

3

## Disclosures

- This presentation will include discussion of off-label use of the following medications:
  - Antipsychotics including pimavanserin
  - Dual orexin receptor antagonists
  - Dextromethorphan-quinidine, dextromethorphan-bupropion, deuterated dextromethorphan-quinidine
  - SL dexmedetomidine
- The content and views presented in this educational program are those of the faculty and do not necessarily represent those of University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

4

# Behavioral Symptoms of Dementia

5

## Background: Types of Dementia

- **Alzheimer's disease (AD):** 60-80% of dementia cases
- **Vascular dementia:** 5-10% of dementia cases
- Other types of dementia:
  - Lewy body dementia
  - Frontotemporal dementia
  - Parkinson's disease dementia
  - Mixed dementia

Goodman RA, et al. *Alzheimers Dement.* 2016  
2024 Alzheimer's disease facts and figures. *Alzheimers Dement.* 2024

6

## Core Dementia Symptoms

- **Decline in cognitive function**
  - Memory
  - Reasoning
  - Concentration
  - Communication
  - Executive functioning
- Motor disturbances
- Personality changes
- Behavioral symptoms

Teixeira AL, et al. *Arq Neuropsiquiatr*. 2023  
American Psychiatric Association, *DSM-5-TR*, 2013

7

## Behavioral Symptoms of Dementia (BSD)

- Often assessed using Neuropsychiatric Inventory tool

Domain	Behavioral Symptoms
Affective	Apathy Anxiety Depression/dysphoria
Agitation	Motor behavior Aggression
Psychosis	Delusions Hallucinations
Sleep disorders	Insomnia Hypersomnia Restless leg syndrome
Disinhibition	Impulsivity Socially inappropriate behaviors (including sexual)

Teixeira AL, et al. *Arq Neuropsiquiatr*. 2023 de Medeiros K, et al. *Int Psychogeriatr*. 2010

8

## Behavioral Symptoms of Dementia (BSD)

- Variable prevalence across dementia subtypes
  - Psychosis: Lewy body > AD
  - Inappropriate social behaviors: Frontotemporal > other subtypes
- BSD often more severe when cognitive symptoms worsen
- Apathy, delusions, and agitation likely most common forms of BSD

Teixeira AL, et al. *Arq Neuropsiquiatr.* 2023

9

## Adverse Outcomes of BSD

Worsening cognitive and functional decline

Caregiver burden

Cost

Utilization of medical service

Institutionalization

Death

Teixeira AL, et al. *Arq Neuropsiquiatr.* 2023 Feast A, et al. *Int Psychogeriatr.* 2016 Sabates J, et al. *Neuropsychol Rev.* 2024

10

## Agitation in Dementia

- May impact >50% of patients with dementia
  - Higher rate in nursing homes
- Features of agitation may include:
  - Pacing
  - Restlessness
  - Repetitive motor and vocal behaviors
  - Aggression (physical or verbal)
    - Hitting, scratching, biting, throwing objects
- May follow circadian rhythm (“sundowning”)

Teixeira AL, et al. *Arq Neuropsiquiatr.* 2023 de Medeiros K, et al. *Int Psychogeriatr.* 2010 Selbaek G, et al. *Int Psychogeriatr.* 2014

11

## Psychosis in Dementia

- Includes delusions and hallucinations
  - Reported in >50% of patients with AD (delusions > hallucinations)
- Can last for many months
- May be distressing

Delusions	Hallucinations
<ul style="list-style-type: none"> <li>• Persecutory</li> <li>• Religious</li> <li>• Jealousy</li> </ul> <p><b>Misidentifications:</b></p> <ul style="list-style-type: none"> <li>• Capgras (hypofamiliarity)</li> <li>• Phantom boarder syndrome</li> <li>• Reduplication</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Visual</b> (simple or complex)</li> <li>• Auditory</li> <li>• Tactile</li> <li>• Olfactory</li> </ul>

Teixeira AL, et al. *Arq Neuropsiquiatr.* 2023 Pessoa RMD, et al. *Dement Neuropsychol.* 2023 Ropacki SA, et al. *Am J Psychiatry.* 2005

12

## Sleep Disorders in Dementia

- Sleep disorders in older patients are a risk factor and predictor for cognitive impairment and dementia
  - Up to 70% of people with AD have a sleep disorder
    - Higher risk in Lewy body dementia
  - Sleep deficits worsen cognitive symptoms
  - Sleep-wake cycle important in production and clearance of proteins relevant to AD
- **Most common:**
  - Insomnia
  - Sleep-disordered breathing
  - Restless leg syndrome
  - Rapid eye movement (REM) sleep behavior disorder

Teixeira AL, et al. *Arq Neuropsiquiatr.* 2023 Casagrande M, et al. *In J Environ Res Public Health.* 2022 Zhao QF, et al. *J Affect Disord.* 2016 Koren T, et al. *Ageing Res Rev.* 2023 Gao F, et al. *Neurosci Lett.* 2021

13

## Affective Symptoms of Dementia

- Apathy = **most common behavioral disorder**
  - Up to 90% in AD
  - Loss of motivation for goal-directed behaviors and cognitive activities
  - Blunted affect
  - Associated with cognitive and functional decline, caregiver burden, institutionalization, mortality
- Depression
- Anxiety

Teixeira AL, et al. *Arq Neuropsiquiatr.* 2023

14

## Audience Question 1

Which of the following is a symptom of agitation in dementia?

- A. Hallucinations
- B. Restless leg syndrome
- C. Throwing objects
- D. Religious preoccupation

15

## Audience Question 1

Which of the following is a symptom of agitation in dementia?

- A. Hallucinations
- B. Restless leg syndrome
- C. Throwing objects**
- D. Religious preoccupation

16



# Current Management of BSD

17

## Goals of Treatment

4

**Define presence and severity of each behavior**

5

**Identify any causative or aggravating factors**

- Sensory deprivation or overstimulation
- Physical discomfort
- Medical comorbidity

6

**Identify non-pharmacologic and pharmacologic interventions**

Kales HC, et al. *Int Psychogeriatr.* 2019 Teixeira AL, et al. *Arq Neuropsiquiatr.* 2023

18

## Non-Pharmacologic Management of BSD

### First-line

#### Mostly focused on caregiver techniques:

- Identify **ABCs** of behavioral changes:
  - A:** Antecedent or triggering event that precedes behavior
  - B:** Problem behavior
  - C:** Consequences of the behavior

#### Non-pharmacologic therapies:

- Encourage activities that patient enjoys
- Redirect and refocus (intervene early)
- Increase social activities
- Eliminate sources of conflict and frustration

Reus VI, et al. *Am J Psychiatry*. 2016 NICE Guidelines: Dementia: assessment, management, and support for people living with dementia and their carers. 2018

19

## Consider Concurrent Medications

- If possible, goal should be to minimize:
  - Anticholinergic load
  - Corticosteroids
  - Benzodiazepines
  - Opioids
  - Z drugs

Bishara D, et al. *Int J Geriatr Psychiatry*. 2014

20

## Pharmacologic Management of BSD

- **Only after non-pharmacologic treatment has been ineffective**
- Should generally still be combined with non-pharmacologic treatment
- **Overarching guideline recommendations:**
  - Any medication used should be part of a comprehensive treatment plan
  - Weigh risks vs. benefit
  - Taper off if no improvement after 4-week trial at adequate dose
  - Attempt taper within 4 months if have positive response

Reus VI, et al. *Am J Psychiatry*. 2016 NICE Guidelines: Dementia: assessment, management, and support for people living with dementia and their carers. 2018

21

## Management of Agitation

1. Intervene early and recognize the patient's behavior
2. Stay calm during the interaction and avoid arguing or reasoning with the patient
3. Approach the patient from the front with slow movements and sit or stand with the patient at eye level
4. Redirect and refocus by distracting the patient, asking about the problem, and gradually turning their attention to something pleasant. Possibly move the patient to a quieter room or activity.

Reus VI, et al. *Am J Psychiatry*. 2016 NICE Guidelines: Dementia: assessment, management, and support for people living with dementia and their carers. 2018

22

## Pharmacologic Management of Agitation

### Weak data:

- Antidepressants (primarily SSRIs)
  - Citalopram
  - Trazodone
- Carbamazepine

### Antipsychotics

- Only in cases of agitation that is **severe, dangerous,** and/or causes **significant distress** to patient
- NOT appropriate for insomnia, pacing, apathy

### Avoid=

- Valproate
- Lithium
- Oxcarbazepine
- Tricyclic antidepressants
- Mirtazapine?
  - No improvement vs. placebo in recent study of AD patients

Reus VI, et al. *Am J Psychiatry*. 2016 NICE Guidelines: Dementia: assessment, management, and support for people living with dementia and their carers. 2018  
Banerjee S, et al. *Health Technol Assess*. 2023

23

## Pharmacologic Management of Psychosis

- Antipsychotics
  - Second-generation antipsychotics (SGAs) preferred
    - First-generation likely as effective but higher mortality risk
    - Higher-potency agents more likely to worsen movement-related symptoms
- **Commonly used:** Risperidone, olanzapine, quetiapine, aripiprazole, brexpiprazole
  - Data is mixed regarding most effective agent and whether antipsychotics adequately treat psychotic symptoms in dementia
    - Possible increased risk of mortality

Teixeira AL, et al. *Arq Neuropsiquiatr*. 2023 Yanusa I, et al. *Adv Ther*. 2022

24

## General Guidelines: Antipsychotics & BPSD

- Start at **low dose** and titrate to **minimum effective dose** as tolerated
- Taper and discontinue after **4 weeks** if no improvement
- SGAs used more often:
  - Risperidone approved for BPSD in some countries (not U.S.)
  - **Brexiprazole** FDA-approved for the treatment of agitation associated with dementia due to Alzheimer's disease in 2023
- **Avoid:**
  - Haloperidol
  - Long-acting injectable antipsychotics

Reus VI, et al. *Am J Psychiatry*. 2016 Brexpiprazole [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2023

25

## Reminder: Antipsychotic Boxed Warning

**WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS**

*See full prescribing information for complete boxed warning.*

- **Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease. (5.1)**

Brexiprazole [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2023

26

## Antipsychotics in Non-AD Dementia

- Lewy body dementia and Parkinson's disease dementia:
  - Antipsychotics may worsen motor features
  - More sensitive to adverse effects

NICE Guidelines: Dementia: assessment, management, and support for people living with dementia and their carers. 2018

27

## Brexpiprazole & Agitation in AD

- FDA-approved in 2023 as **scheduled** treatment for agitation associated with AD

Evidence leading to approval:

- 2 randomized, 12-week, parallel-arm, double-blind, placebo-controlled, multi-site studies
  - Study 1: Fixed-dose brexpiprazole 1mg or 2 mg/day
  - Study 2: Flexible-dose brexpiprazole 0.5-2mg/day
- Included adults 55-90 years of age with diagnosis of probable AD with baseline symptoms of agitation or aggression

Grossberg GT, et al. *Am J Geriatr Psychiatry*. 2020

28

# Brexpiprazole & Agitation in AD

- Primary outcome: Change in Cohen-Mansfield Agitation Inventory (CMAI) from baseline to week 12

Treatment Group	Baseline Mean CMAI Score	Change from Baseline at Week 12, Adjusted Mean (SE)	P-value	Cohen's d Effect Size
<b>Study 1: Fixed-dose</b>				
Brexpiprazole 2 mg (n=138)	71.0	-21.6 (1.3)	0.040	-0.25
Brexpiprazole 1 mg (n=134)	70.5	-17.6 (1.3)	0.90	0.02
Placebo (n=131)	72.2	-17.8 (1.3)		
<b>Study 2: Flexible-dose</b>				
Brexpiprazole 0.5-2mg*	71.5	-18.9 (1.2)	0.15	-0.18
Placebo	68.6	-16.5 (1.1)		


\*Post-hoc analysis found statistically significant improvement among subjects titrated to 2 mg by week 4

Grossberg GT, et al. *Am J Geriatr Psychiatry*. 2020 Meunier J, et al. *Front Neurol*. 2024

29

# Brexpiprazole & Agitation in AD

FIGURE 3. Primary endpoint in Study 1: effects of brexpiprazole on symptoms of agitation (CMAI Total).




Notes: MMRM analysis. Mean (SD) CMAI Total score at baseline: placebo, 72.2 (17.9); brexpiprazole 1 mg, 70.5 (16.0); brexpiprazole 2 mg, 71.0 (16.6). CMAI: Cohen-Mansfield Agitation Inventory; MMRM: mixed model for repeated measures; SD: standard deviation; SE: standard error. \* $t_{(316)} = -2.06, p = 0.040$  versus placebo.

Grossberg GT, et al. *Am J Geriatr Psychiatry*. 2020

30

FIGURE 5. Primary endpoint in Study 2: effects of brexpiprazole on symptoms of agitation (CMAI Total) in a) total efficacy sample and b) subgroup titrated to 2 mg (or equivalent placebo) at Week 4 (post hoc analysis).



Grossberg GT, et al. *Am J Geriatr Psychiatry*. 2020

## Audience Question 2

A 64-year-old patient has a PMH of AD, hypertension, urinary incontinence, and insomnia. Recently, they have been increasingly agitated throughout both the day and night. Symptoms primarily include pacing and verbally repeating the same phrases many times. Non-pharmacologic intervention is mildly effective, but the patient's caregiver is requesting pharmacologic intervention as well.

**Current medications:**

- Amlodipine 10 mg po daily
- Oxybutynin 10 mg po daily
- Diphenhydramine 25 mg po nightly prn insomnia
- Cetirizine 10 mg po daily
- Melatonin 6 mg po nightly

31

## Audience Question 2

Which of the following is the best first step in managing the patient's agitation?

- A. Discontinue melatonin
- B. Reduce anticholinergic load
- C. Initiate mirtazapine

32



## Audience Question 2

Which of the following is the best first step in managing the patient's agitation?

- A. Discontinue melatonin
- B. Reduce anticholinergic load**
- C. Initiate mirtazapine

33

## Audience Question 3

The patient and caregiver agree to discontinuation of the cetirizine and diphenhydramine. They feel strongly that the oxybutynin improves their quality of life by allowing them to not become incontinent of urine overnight. Unfortunately, several weeks later the agitation symptoms persist. Which of the following is the best recommendations at this time?

- A. Initiate citalopram
- B. Initiate haloperidol
- C. Initiate risperidone
- D. Initiate valproate

34

## Audience Question 3

The patient and caregiver agree to discontinuation of the cetirizine and diphenhydramine. They feel strongly that the oxybutynin improves their quality of life by allowing them to not become incontinent of urine overnight. Unfortunately, several weeks later the agitation symptoms persist. Which of the following is the best recommendations at this time?

- A. Initiate citalopram
- B. Initiate haloperidol
- C. Initiate risperidone
- D. Initiate valproate

35

## Pharmacologic Management of Sleep Disorders

- Limited data
- Guidelines recommend against use of melatonin although commonly used
  - No positive evidence for melatonin receptor agonists (ramelteon)
- Significant adverse effects associated with benzodiazepines, Z drugs
- **Preferred:**
  - Trazodone
  - Orexin receptor antagonists

NICE Guidelines: Dementia: assessment, management, and support for people living with dementia and their carers. 2018 Teixeira AL, et al. *Arq Neuropsiquiatr.* 2023 Javed B, et al. *Expert Rev Neurother.* 2023

36

## Orexin Receptor Antagonists in Dementia

Orexin (hypocretin): Neuropeptides that modulates sleep-wake cycle

- Higher levels = increased wakefulness

Orexin system may be dysregulated in dementia

- Positive correlation between biomarkers of AD and orexin levels

Gao F, et al. *Neurosci Lett.* 2021. Suvorexant [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2014

37

## Orexin Receptor Antagonists in Dementia

- Currently available medications are **dual** orexin receptor antagonists (DORAs) → antagonize orexin-1 and orexin-2 receptors
  - Suvorexant
    - FDA-approved for sleep disorders in AD in 2020
  - Lemborexant
  - Daridorexant
- Seltorexant = selective orexin-2 receptor antagonist
  - In phase 2 studies for probable AD with clinically significant agitation/aggression

Gao F, et al. *Neurosci Lett.* 2021. Suvorexant [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2014

38

## DORAs in Dementia

Suvorexant	Lemborexant
<p>Phase III randomized, double-blind, placebo-controlled trial (N=285)</p> <ul style="list-style-type: none"> <li>• Included pts with mild-to-moderate probable AD</li> <li>• Sleep assessed by overnight polysomnography in sleep laboratory</li> <li>• Improvement in total sleep time of 28 minutes compared to placebo (<math>p &lt; 0.01</math>) after 4 weeks</li> </ul> <p>Case series (n=4) reported improvement in “nocturnal delirium” in AD for pts who had failed other pharmacologic options</p>	<p>Phase II randomized, double-blind, placebo-controlled trial (N=62)</p> <ul style="list-style-type: none"> <li>• Included pts with diagnosis of AD and irregular sleep-wake rhythm disorder</li> <li>• 3 out of the 4 doses studied statistically significantly reduced number of limb movements (restlessness) after 4 weeks</li> <li>• Decrease in sleep during the day for 2 of 4 doses studied</li> </ul>

Roland JP, et al. *Drugs Aging*. 2021 Herring WJ, et al. *Alzheimers Dement*. 2020 Hanazawa T, et al. *Clin Psychopharmacol Neurosci*. 2019 Moline M, et al. *J Prev Alzheimers Dis*. 2021

39

## Pharmacologic Management of Affective Symptoms

SSRIs

Trazodone

Teixeira AL, et al. *Arq Neuropsiquiatr*. 2023

40

# Emerging Therapies

41

**Emerging Therapies**

- Pimavanserin
- Dextromethorphan combination medications
- Dexmedetomidine

42

## Pimavanserin (Nuplazid) & BSD

- FDA-approved in 2016 for Parkinson's disease psychosis (PDP)
- Considered a second-generation antipsychotic, however very different mechanism:
  - Inverse agonist and antagonist of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors
  - Negligible affinity for dopamine receptors
- In trial of PDP, results showed that patients with cognitive impairment had more robust response to treatment
  - Now being studied for treatment of dementia-related psychosis

Pimavanserin [package insert]. San Diego, CA: Acadia Pharmaceuticals Inc.; 2023 Espay AJ, et al. *Mov Disord*. 2018

43

## Pimavanserin and Dementia-Related Psychosis

- Phase II trial showed efficacy in psychosis in possible or probable AD after 6 weeks (but not after 12 weeks)
- Phase III trial (HARMONY trial) of pimavanserin 34 mg daily:
  - 12-week open-label period followed by double-blind placebo-controlled period of up to 26 weeks for patients who met criteria for treatment response
  - Included adults 50-90 years of age who met criteria for Parkinson's disease dementia, Lewy body dementia, AD, frontotemporal dementia, or vascular dementia
    - Psychotic symptoms for  $\geq 2$  months

Ballard C, et al. *Lancet Neurol*. 2018 Tariot PN, et al. *N Engl J Med*. 2021

44

## HARMONY Trial, Continued

- Primary endpoint: Time from randomization to relapse of psychosis
- N=392 in open-label phase
- N = 217 in double-blind phase
- Primary dementia subtypes: AD > PDP > vascular > Lewy body > frontotemporal
- **Relapse rate at time of interim analysis (statistically significant):**
  - 13% in pimavanserin group
  - 28% in placebo group
- **Fewer patients discontinued pimavanserin (22%) compared to placebo (38%)**

Ballard C, et al. *Lancet Neurol.* 2018 Tariot PN, et al. *N Engl J Med.* 2021

45

## Audience Question 4

A 71-year-old patient with vascular dementia recently started voicing the belief that unknown people were living in his attic. He states that he can hear the intruders talking during the night but they are able to hide whenever someone goes up to check. The patient is extremely distressed about this and is trying to obtain a firearm to protect his family from these intruders.

Which of the following pharmacologic recommendations may be appropriate? Select all that apply.

- A. Brexpiprazole
- B. Trazodone
- C. Pimavanserin
- D. Citalopram
- E. Haloperidol

46

## Audience Question 4

A 71-year-old patient with vascular dementia recently started voicing the belief that unknown people were living in his attic. He states that he can hear the intruders talking during the night but they are able to hide whenever someone goes up to check. The patient is extremely distressed about this and is trying to obtain a firearm to protect his family from these intruders.

Which of the following pharmacologic recommendations may be appropriate? Select all that apply.

- A. **Brexpiprazole**
- B. Trazodone
- C. **Pimavanserin**
- D. Citalopram
- E. Haloperidol

47

## Audience Question 5

The patient has significant improvement in symptoms following the initiation of brexpiprazole. However, they are still very restless at night and wake up frequently. They report being “exhausted” each day. Which of the following would be the best pharmacologic option?

- A. Quetiapine
- B. Melatonin
- C. Eszopiclone
- D. Suvorexant

48



## Audience Question 5

The patient has significant improvement in symptoms following the initiation of brexpiprazole. However, they are still very restless at night and wake up frequently. They report being “exhausted” each day. Which of the following would be the best pharmacologic option?

- A. Quetiapine
- B. Melatonin
- C. Eszopiclone
- D. Suvorexant**

49

## Dextromethorphan (DTX) & BSD

- DTX: Multiple mechanisms:
  - Uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist
  - Sigma-1 receptor agonist
  - Serotonin and norepinephrine reuptake inhibitor
  - Nicotinic receptor antagonist
- Mechanism in BSD unclear
- May be formulated with CYP2D6 inhibitors (quinidine, bupropion) to inhibit metabolism and extend bioavailability

50

<b>Dextromethorphan (DTX) Combinations</b>			
	<b>DTX-Quinidine</b>	<b>Deuterated DTX-quinidine</b>	<b>DTX-Bupropion</b>
<b>Brand name</b>	Nuedexta	N/A (AVP-786)	Auvelity
<b>FDA-approved indications</b>	Psuedobulbar affect	N/A	Major depressive disorder
<b>Studies in dementia</b>	<p><b>Phase 2 study: Probable AD with agitation</b></p> <ul style="list-style-type: none"> <li>• N=220</li> <li>• Significant reduction in agitation/aggression scores compared to placebo after 10 weeks</li> </ul>	<p><b>Two phase 3 studies: Moderate-to-severe agitation and probable AD</b></p> <ul style="list-style-type: none"> <li>• Contradictory results</li> <li>• Full datasets not published</li> </ul> <p><b>TRIAD-1:</b> Statistically significant decrease in agitation (N=410) with one of the two doses assessed after 12 weeks</p> <p><b>TRIAD-2:</b> Did not replicate findings of TRIAD-1 in similar patient population (N=522)</p>	<p>Currently in trials for agitation related to AD</p> <p>Early data suggests significant reduction in agitation symptoms in AD</p>
<b>Common ADEs</b>	Falls Diarrhea UTI	Sinus bradycardia Nausea, vomiting UTI Falls Agitation	Diarrhea Xerostomia Headache Sexual dysfunction Dizziness

Khoury R. *Neural Regen Res.* 2022 Ward K, et al. *Expert Opin Investig Drugs.* 2022 Cummings JL, et al. *JAMA.*2015

51

## **Dexmedetomidine & BSD**

- FDA-approved **sublingual** dexmedetomidine in 2022 for agitation associated with schizophrenia or bipolar disorder
- Studies investigating use in BSD:
  - **TRANQUILITY II:** Phase 3
    - Treatment of acute psychomotor agitation (kicking, biting, flailing) in dementia
    - One of the two doses studied is reported to have shown significant reduction in Positive and Negative Syndrome Scale-Excited Component (PEC) score 1 hour and 2 hours after administration
  - **TRANQUILITY III:** Phase 3
    - Probable AD and resided in care facility → terminated early
  - **Planned:** Phase 2 study assessing dexmedetomidine transdermal patch

Murphy KS, et al. *J Am Geriatr Soc.* 2024.

52

## Summary of Emerging Therapies:

**Psychosis in dementia:**

- May be helpful:
- Pimavanserin → phase 3 trials showed lower relapse and discontinuation rates in psychosis associated with multiple types of dementia vs. placebo

**Agitation in dementia:**

- May be helpful in AD:
- DTX-quinidine → phase 2 study showed reduction in agitation/aggression vs. placebo
- Not enough data:
- Deuterated DTX-quinidine
- DTX-bupropion
- Dexmedetomidine (SL)

53

## Summary

	Agitation	Psychosis	Sleep
<b>Current therapy</b>	<ul style="list-style-type: none"> <li>• Antidepressants</li> <li>• Carbamazepine</li> <li>• Antipsychotics if severe, dangerous, or causing significant distress</li> </ul>	<ul style="list-style-type: none"> <li>• Second-generation antipsychotics</li> </ul>	<ul style="list-style-type: none"> <li>• Trazodone</li> <li>• Dual orexin receptor antagonists</li> </ul>
<b>Emerging therapy</b>	<ul style="list-style-type: none"> <li>• DTX-quinidine</li> <li>• <i>Deuterated DTX-quinidine</i></li> <li>• <i>DTX-bupropion</i></li> <li>• <i>Dexmedetomidine (SL)</i></li> </ul>	<ul style="list-style-type: none"> <li>• Pimavanserin</li> </ul>	<ul style="list-style-type: none"> <li>• Orexin receptor antagonist (may be more for agitation)</li> </ul>

54

## Summary

1. Agitation, psychosis, and sleep disturbances are distinct behavioral symptoms of dementia that require separate assessment and treatment
2. Antipsychotics should be reserved for cases of psychosis or for agitation that is severe, dangerous, or causes significant distress
3. New treatment options may become available to help target BSD in the future

55

## References

1. 2024 Alzheimer's disease facts and figures. *Alzheimers Dement.* 2024;20(5):3708-21
2. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders* (5<sup>th</sup> ed., text rev). 2022.
3. Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. *Lancet Neurol.* 2018;17(3):213-22
4. Banerjee S, Farina N, Henderson C, et al. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial. *Health Technol Assess.* 2023;27(23):1-108
5. Bishara D, Harwood D. Safe prescribing of physical health medication in patients with dementia. *Int J Geriatr Psychiatry.* 2014;29(12):1230-41
6. Casagrande M, Forte G, Favieri F, Corbo I. Sleep quality and aging: A systematic review on healthy older people, mild cognitive impairment, and Alzheimer's disease. *Int J Environ Res Public Health.* 2022;19(14):8457
7. Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: A randomized clinical trial. *JAMA.* 2015;314(12):1242-54
8. de Medeiros K, Robert P, Gauthier S, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): Reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. *Int Psychogeriatr.* 2010;22(6):984-94
9. Espay AJ, Guskey MT, Norton JC, et al. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. *Mov Disord.* 2018;33(11):1769-76
10. Feast A, Moniz-Cook E, Stoner C, et al. A systematic review of the relationship between behavioral and psychological symptoms (BPSD) and caregiver well-being. *Int Psychogeriatr.* 2016;28(11):1761-74
11. Gao F, Liu T, Tuo M, et al. The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target. *Neurosci Lett.* 2021;765:136247
12. Goodman RA, Lochner KA, Thambisetty M, et al. Prevalence of dementia subtypes in U.S. Medicare fee-for service beneficiaries, 2011-2013. *Alzheimers Dement.* 2016;13(1):28-37
13. Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. *Am J Geriatr Psychiatry.* 2020;28(4):383-400
14. Hanazawa T, Kamijo Y. Effect of suvorexant on nocturnal delirium in elderly patients with Alzheimer's disease: A case-series study. *Clin Psychopharmacol. Neurosci.* 2019;17(4):547-50
15. Herring WJ, Ceasay P, Snyder E, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. *Alzheimers Dement.* 2020;16(3):541-51
16. Javed B, Javed A, Know CS, et al. Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer's disease. *Expert Rev Neurother.* 2023;23(6):501-14

56

## References, contd

17. Kales HC, Lyketsos CG, Miller EM, et al. Management of behavioral and psychological symptoms in people with Alzheimer's disease: An international Delphi consensus. *Int Psychogeriatr.* 2019;31(1):83-90
18. Khoury R. Deuterated dextromethorphan/quinidine for agitation in Alzheimer's disease. *Neural Regen Res.* 2022;17(5):1013-14
19. Koren T, Fisher E, Webster L, et al. Prevalence of sleep disturbances in people with dementia living in the community: A systematic review and meta-analysis. *Ageing Res Rev.* 2023;83:101782
20. Meunier J, Creel K, Loubert A, et al. Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementia. *Front Neurol.* 2024;15:1379062
21. Moline M, Thein S, Bsharat M, et al. Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial. *J Prev Alzheimers Dis.* 2021;8(1):7-18
22. Murphy KS, Golden JC, Tampi RR. Dexmedetomidine for agitation in dementia: Current data and future direction. *J Am Geriatr Soc.* 2024.
23. National Institute for Health and Care Excellence (NICE). Dementia: Assessment, management, and support for people living with dementia and their carers. London (UK): National Institute for Health and Clinical Excellence. 2018
24. Pessoa RMD, Maximiano-Barreto MA, Lambert L, et al. The frequency of psychotic symptoms in types of dementia: A systematic review. *Dement Neuropsychol.* 2023;17:e20220044
25. Reus VI, Fochtman LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. *Am J Psychiatry.* 2016;173(5):543-6
26. Roland JP, Bliwise DL. *Drugs Aging.* 2021;38(11):951-66
27. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: A review of 55 studies published from 1990 to 2003. *Am J Psychiatry.* 2005;162(11):2022-30
28. Sabates J, Chiu W-H, Loi S, et al. The associations between neuropsychiatric symptoms and cognition in people with dementia: A systematic review and meta-analysis. *Neuropsychol Rev.* 2024;34(2):581-97
29. Selbaek G, Engedal K, Benth JS, et al. The course of neuropsychiatric symptoms in nursing-home patients with dementia over a 53-month follow-up period. *Int Psychogeriatr.* 2014;26(1):81-91
30. Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of pimavanserin in dementia-related psychosis. *N Engl J Med.* 2021;385(4):309-19
31. Teixeira AL, Rocha NP, Gatchel J, et al. Behavioral or neuropsychiatric symptoms of Alzheimer's disease: From psychopathology to pharmacological management. *Arq Neuropsiquiatr.* 2023;81(12):1152-62
32. Ward K, Citrome L. AXS-05: An investigational treatment for Alzheimer's disease-associated agitation. *Expert Opin Investig Drugs.* 2022;31(8):773-80
33. Yanusa I, Rashid N, Demos GN, et al. Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment of dementia-related psychosis: A network meta-analysis. *Adv Ther.* 2022;39(5):1993-2008
34. Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. *J Affect Disord.* 2016;190:264-71

57

# Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia

Kristin Waters, PharmD, BCPS, BCPP  
University of Connecticut  
Assistant Clinical Professor

58